Skip to Content
Merck
CN

PMI: a ΔΨm independent pharmacological regulator of mitophagy.

Chemistry & biology (2014-12-03)
Daniel A East, Francesca Fagiani, James Crosby, Nikolaos D Georgakopoulos, Hélène Bertrand, Marjolein Schaap, Adrian Fowkes, Geoff Wells, Michelangelo Campanella
ABSTRACT

Mitophagy is central to mitochondrial and cellular homeostasis and operates via the PINK1/Parkin pathway targeting mitochondria devoid of membrane potential (ΔΨm) to autophagosomes. Although mitophagy is recognized as a fundamental cellular process, selective pharmacologic modulators of mitophagy are almost nonexistent. We developed a compound that increases the expression and signaling of the autophagic adaptor molecule P62/SQSTM1 and forces mitochondria into autophagy. The compound, P62-mediated mitophagy inducer (PMI), activates mitophagy without recruiting Parkin or collapsing ΔΨm and retains activity in cells devoid of a fully functional PINK1/Parkin pathway. PMI drives mitochondria to a process of quality control without compromising the bio-energetic competence of the whole network while exposing just those organelles to be recycled. Thus, PMI circumvents the toxicity and some of the nonspecific effects associated with the abrupt dissipation of ΔΨm by ionophores routinely used to induce mitophagy and represents a prototype pharmacological tool to investigate the molecular mechanisms of mitophagy.

MATERIALS
Product Number
Brand
Product Description

Roche
cOmplete ULTRA Tablets, Mini, EDTA-free, EASYpack Protease Inhibitor Cocktail, Tablets supplied in foil blister packs.